주식/증권 ➡️ 중립 Outlook Therapeutics targets more than $500M peak annual LYTENAVA sales by 2030 as it forecasts $50M-$75M first-year net revenue Seeking Alpha - Market News 2026/08/14 17:08:02 8회 원문 기사 보기